Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Cadiz – page 8

220 clinical trials in Cadiz, Spain across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Cadiz at a glance
220
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

220 trials in Cadiz

Open in trial search

Breast cancer

Recruiting

Long-Term Study on Early Stage Breast Cancer Patients Using Capecitabine, Gemcitabine, and Paclitaxel

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer De Mama

Study on Early Use of Candesartan vs Placebo for People with Genetic Risk of Dilated Cardiomyopathy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Candesartan Cilexetil
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda

Obesity+1

Not yet recruiting

Phase 3 Double‑Blind Study of Olatorepatide for Weight Loss in Adults with Overweight or Obesity Without Diabetes

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Olatorepatide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Atrial fibrillation

Not yet recruiting

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:REGN9933
  • Sponsor:Regeneron Pharmaceuticals Inc.

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Type 2 diabetes mellitus+2

Not yet recruiting

Efficacy and Safety of Olatorepatide in Adults with Overweight or Obesity and Type 2 Diabetes

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Olatorepatide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Type 2 diabetes mellitus

Not yet recruiting

Study of zenagamtide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk uncontrolled on oral medications

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Malignant peritoneal neoplasm+2

Not yet recruiting

A Phase 3 Study of Raludotatug Deruxtecan With or Without Bevacizumab as Maintenance Therapy in Patients With Platinum‑Sensitive Recurrent Ovarian Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.

Cardiovascular disorder+2

Not yet recruiting

Phase III Study Evaluating Efficacy and Safety of Petrelintide in Participants with Overweight or Obesity and Established Cardiovascular Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Petrelintide
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer

Not yet recruiting

Phase III Study of Izalontamab Brengitecan with Drug Combination versus Osimertinib Alone in First‑Line EGFR‑Mutated Advanced or Metastatic Non‑Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Conjunctivitis allergic+1

Not yet recruiting

Efficacy and safety of Depigoid Olea 1000 DPP/ml compared with placebo in patients with moderate to severe allergic rhinoconjunctivitis due to olive pollen

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:LETI Pharma S.L.U.

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Cadiz

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on bladder cancer treatments, including studies of mitomycin C delivery and immunotherapy approaches. Research extends to pancreatic adenocarcinoma and triple-negative breast cancer, evaluating new therapeutic combinations.

  • Non-muscle invasive bladder cancer treatments
  • Neoadjuvant therapy for pancreatic cancer
  • Immunotherapy combinations

Studies are exploring both localized and advanced disease states with emphasis on improving survival rates.

02 Immunology and Allergies

Groundbreaking research in allergic conditions and autoimmune disorders, including studies on hidradenitis suppurativa and innovative immunotherapy approaches for allergic rhinitis.

  • Allergen-specific immunotherapy
  • Inflammatory skin conditions
  • Respiratory allergies

Trials aim to evaluate novel therapeutic agents and treatment protocols for chronic conditions.

03 Transplant Medicine

Studies focusing on improving outcomes in kidney transplantation, particularly addressing delayed graft function through innovative therapeutic approaches.

  • Prevention of graft rejection
  • Post-transplant complications
  • Novel immunosuppressive strategies

Research aims to enhance transplant success rates and reduce post-operative complications.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.